On November 10, TG Therapeutics rose 5.51% in Regular Trading, trading at $67.12, with turnover of $32.48 million.
The move followed the company’s latest quarterly report, which showed third-quarter revenue of $259.9 million, above market expectations of about $245.5 million, while total global revenue guidance was raised to about $1.0 billion from $950 million previously.
Diluted EPS was $0.35, down from $2.43 a year earlier and slightly below some expectations, but revenue increased from $161.7 million a year ago, indicating that continued commercialization of BRIUMVI remained the central support for the stock reaction. The earnings release was issued on November 9, making the updated operating outlook the clearest identified catalyst for the latest move.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments